ALK and lung cancer: Our discovery of PI3Kβ as a target to enhance ALKi sensitivity in ALK‐rearranged lung cancer is unexpected, as we here found combinatorial ALKi/PI3Kβi sensitivity independent of PTEN/PIK3CA mutations or resistance to PI3Kα inhibitors.